Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives

Parkinsonism is a progressive motor disease that affects 1.5 million Americans and is the second most common neurodegenerative disease after Alzheimer’s. Typical neuropathological features of Parkinson’s disease (PD) include degeneration of dopaminergic neurons located in the pars compacta of the substantia nigra that project to the striatum (nigro-striatal pathway) and depositions of cytoplasmic fibrillary inclusions (Lewy bodies) which contain ubiquitin and α-synuclein. The cardinal motor signs of PD are tremors, rigidity, slow movement (bradykinesia), poor balance, and difficulty in walking (Parkinsonian gait). In addition to motor symptoms, non-motor symptoms that include autonomic and psychiatric as well as cognitive impairments are pressing issues that need to be addressed. Several different mechanisms play an important role in generation of Lewy bodies; endoplasmic reticulum (ER) stress induced unfolded proteins, neuroinflammation and eventual loss of dopaminergic neurons in the substantia nigra of mid brain in PD. Moreover, these diverse processes that result in PD make modeling of the disease and evaluation of therapeutics against this devastating disease difficult. Here, we will discuss diverse mechanisms that are involved in PD, neuroprotective and therapeutic strategies currently in clinical trial or in preclinical stages, and impart views about strategies that are promising to mitigate PD pathology.

[1]  A. Björklund,et al.  Characterization of Lewy body pathology in 12‐ and 16‐year‐old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[2]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[3]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Weller,et al.  Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. , 1994, Journal of neural transmission. Supplementum.

[5]  B. Giasson,et al.  Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. , 2000, The Journal of biological chemistry.

[6]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[7]  D. Maraganore,et al.  Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study , 2006, Neurology.

[8]  A. Lang,et al.  The nonmotor symptoms of Parkinson's disease—An overview , 2010, Movement disorders : official journal of the Movement Disorder Society.

[9]  F. Horak,et al.  Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. , 2011, Archives of neurology.

[10]  R. Barker,et al.  Neural grafting in Parkinson's disease Problems and possibilities. , 2010, Progress in brain research.

[11]  A. Siderowf,et al.  Preclinical diagnosis of parkinson’s disease: Are we there yet? , 2006, Current neurology and neuroscience reports.

[12]  D. Guay Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. , 2006, The American journal of geriatric pharmacotherapy.

[13]  A. Schapira,et al.  TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial , 2006, The Lancet Neurology.

[14]  Alexander Hammers,et al.  In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.

[15]  H. Gendelman,et al.  Nitrated alpha‐synuclein‐activated microglial profiling for Parkinson’s disease , 2008, Journal of neurochemistry.

[16]  W. Jagust,et al.  Safety and tolerability of putaminal AADC gene therapy for Parkinson disease , 2009, Neurology.

[17]  A. Glavaski-Joksimovic,et al.  Mesenchymal stem cells and neuroregeneration in Parkinson's disease , 2013, Experimental Neurology.

[18]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[19]  C. Gamba,et al.  Neuroprotective effects of human umbilical cord mesenchymal stromal cells in an immunocompetent animal model of Parkinson's disease , 2012, Journal of Neuroimmunology.

[20]  M. Selley Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice , 2005, Brain Research.

[21]  F. Binkofski,et al.  Nonmotor symptoms in genetic Parkinson disease. , 2010, Archives of neurology.

[22]  M. Miller,et al.  CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. , 1999, The Journal of pharmacology and experimental therapeutics.

[23]  T. Hökfelt,et al.  Effect of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neurons , 1973, The Journal of pharmacy and pharmacology.

[24]  R. Bakay,et al.  Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys , 2006, Annals of neurology.

[25]  P. Mcgeer,et al.  Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins , 2004, Acta Neuropathologica.

[26]  H. Allain,et al.  Disease-modifying drugs and Parkinson's disease , 2008, Progress in Neurobiology.

[27]  Marios Politis,et al.  Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants , 2010, Science Translational Medicine.

[28]  Sunhong Kim,et al.  Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.

[29]  J. L. Eberling,et al.  Results from a phase I safety trial of hAADC gene therapy for Parkinson disease , 2008, Neurology.

[30]  M. Beal,et al.  NMDA antagonists partially protect against MPTP induced neurotoxicity in mice , 1993, Neuroreport.

[31]  P. Brundin,et al.  The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat , 2006, Neurobiology of Disease.

[32]  Ross,et al.  Relationship between caffeine intake and parkinson disease , 2000, JAMA.

[33]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[34]  Minoru Harada,et al.  Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.

[35]  The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations , 2003, Movement disorders : official journal of the Movement Disorder Society.

[36]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[37]  E. Masliah,et al.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.

[38]  Karl Kieburtz,et al.  Issues in neuroprotection clinical trials in Parkinson’s disease , 2006, Neurology.

[39]  Y. Agid,et al.  Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[40]  T. van Laar,et al.  Chronic stimulation of the subthalamic nucleus increases daily on-time without dyskinesia in advanced Parkinson's disease. , 2006, Parkinsonism & related disorders.

[41]  B. E. Staveley,et al.  parkin counteracts symptoms in a Drosophila model of Parkinson's disease , 2004, BMC Neuroscience.

[42]  M. Tansey,et al.  Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention , 2007, Experimental Neurology.

[43]  H. Berendse,et al.  Idiopathic hyposmia as a preclinical sign of Parkinson's disease , 2004, Annals of neurology.

[44]  L. Findley,et al.  Olfactory function in essential tremor: A deficit unrelated to disease duration or severity , 2003, Neurology.

[45]  M. Gates,et al.  Stem cell-derived dopamine neurons for brain repair in Parkinson's disease. , 2010, Regenerative medicine.

[46]  H. Federoff,et al.  Gene therapeutic strategies for neurodegenerative diseases , 2005 .

[47]  F. Horak,et al.  Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease , 2010, Neurology.

[48]  O. Hornykiewicz,et al.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.

[49]  E. Melamed,et al.  Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease. , 2007, Journal of neural transmission. Supplementum.

[50]  M. Hernán,et al.  Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease , 2006, Neurology.

[51]  A. Hung,et al.  Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? , 2007, Current opinion in neurology.

[52]  G. Ferrari,et al.  The non-immunosuppressive immunophilin ligand GPI-1046 potently stimulates regenerating axon growth from adult mouse dorsal root ganglia cultured in Matrigel , 2002, Neuroscience.

[53]  Ninds Net-Pd Investigators A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. , 2006 .

[54]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[55]  M. Merello,et al.  Prospective randomized 1-year follow-up comparison of bilateral subthalamotomy versus bilateral subthalamic stimulation and the combination of both in Parkinson's disease patients: a pilot study , 2008, British journal of neurosurgery.

[56]  Nicholas W Wood,et al.  A common LRRK2 mutation in idiopathic Parkinson's disease , 2005, The Lancet.

[57]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[58]  D. Weintraub,et al.  Parkinson's disease--Part 3: Neuropsychiatric symptoms. , 2008, The American journal of managed care.

[59]  W. Scheper,et al.  Activation of the unfolded protein response in Parkinson's disease. , 2007, Biochemical and biophysical research communications.

[60]  Elaine Holmes,et al.  The application of NMR-based metabonomics in neurological disorders , 2006, NeuroRX.

[61]  M. Chesselet,et al.  Modelling of Parkinson's disease in mice , 2011, The Lancet Neurology.

[62]  J. Obeso,et al.  Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. , 2005, Brain : a journal of neurology.

[63]  D. Brocks Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. , 1999, Journal of Pharmacy & Pharmaceutical Sciences.

[64]  David Eidelberg,et al.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial , 2007, The Lancet.

[65]  K. Sethi,et al.  A controlled trial of antidepressants in patients with Parkinson’s disease and depression , 2009, Current neurology and neuroscience reports.

[66]  A. Schapira Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease , 2009, Neurology.

[67]  Manjit,et al.  Neurology , 1912, NeuroImage.

[68]  D. Standaert,et al.  Targets for neuroprotection in Parkinson's disease. , 2009, Biochimica et biophysica acta.

[69]  A. Hofman,et al.  Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease , 2007, Neuroepidemiology.

[70]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.

[71]  Changan Jiang,et al.  Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.

[72]  D. Leibfritz,et al.  Free radicals and antioxidants in normal physiological functions and human disease. , 2007, The international journal of biochemistry & cell biology.

[73]  C. Marsden,et al.  Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.

[74]  A. Carlsson,et al.  A fluorimetric method for the determination of dopamine (3-hydroxytyramine). , 1958, Acta physiologica Scandinavica.

[75]  Lindy D Wood Clinical Review and Treatment of Select Adverse Effects of Dopamine Receptor Agonists in Parkinson’s Disease , 2010, Drugs & aging.

[76]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[77]  M. Beal,et al.  Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity , 1998, Experimental Neurology.

[78]  E. Hirsch,et al.  Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease. , 1999, Advances in neurology.

[79]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[80]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[81]  Stanley Fahn,et al.  Does levodopa slow or hasten the rate of progression of Parkinson’s disease? , 2005, Journal of Neurology.

[82]  H. Reichmann,et al.  Olfactory dysfunction as a diagnostic marker for Parkinson’s disease , 2009, Expert review of neurotherapeutics.

[83]  K. Paumier,et al.  Transplantation of subventricular zone neural precursors induces an endogenous precursor cell response in a rat model of Parkinson's disease , 2009, The Journal of comparative neurology.

[84]  R. Barker,et al.  The search for biomarkers in Parkinson’s disease: a critical review , 2008, Expert review of neurotherapeutics.

[85]  Makoto Hashimoto,et al.  Transgenic models of alpha-synuclein pathology: past, present, and future. , 2003, Annals of the New York Academy of Sciences.

[86]  D. Perl,et al.  Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.

[87]  A H V Schapira,et al.  Present and future drug treatment for Parkinson’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[88]  P. Riederer,et al.  Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.

[89]  N. Hattori,et al.  An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.

[90]  P. Leigh,et al.  Treatment of parkinsonism with bromocriptine. , 1974, Lancet.

[91]  Vesna Sossi,et al.  A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.

[92]  Shao-Hua Yang,et al.  Pyruvate protects mitochondria from oxidative stress in human neuroblastoma SK-N-SH cells , 2007, Brain Research.

[93]  H. Ichinose,et al.  Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease , 1999, Neuroscience Letters.

[94]  Howard E. Gendelman,et al.  Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.

[95]  G. Celesia,et al.  Psychosis and other psychiatric manifestations of levodopa therapy. , 1970, Archives of neurology.

[96]  A. J. Valente,et al.  Novel Regulation of Parkin Function through c-Abl-Mediated Tyrosine Phosphorylation: Implications for Parkinson's Disease , 2011, The Journal of Neuroscience.

[97]  C. Olanow,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[98]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[99]  HOMAS,et al.  ASSOCIATION BETWEEN EARLY-ONSET PARKINSON ’ S DISEASE AND MUTATIONS IN THE PARKIN GENE , 2000 .

[100]  Joshua J. Neumiller,et al.  Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. , 2010, The American journal of geriatric pharmacotherapy.

[101]  Y. Agid,et al.  Levodopa: why the controversy? , 2002, The Lancet.

[102]  Paola Piccini,et al.  Functional brain imaging in the differential diagnosis of Parkinson's disease , 2004, The Lancet Neurology.

[103]  R. Godwin-Austen,et al.  Comparison of the effects of bromocriptine and levodopa in Parkinson's disease. , 1977, Journal of neurology, neurosurgery, and psychiatry.

[104]  Lewis E Kazis,et al.  Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease , 2007, BMC medicine.

[105]  E. Louis,et al.  Olfactory dysfunction in essential tremor: A deficit unrelated to disease duration or severity , 2002 .

[106]  Hyon K. Choi,et al.  Diet, urate, and Parkinson's disease risk in men. , 2008, American journal of epidemiology.

[107]  M. Feany,et al.  α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.

[108]  K. Jellinger,et al.  Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.

[109]  A. Björklund,et al.  Intracerebral Grafting of Dopamine Neurons , 1987, Annals of the New York Academy of Sciences.

[110]  B. Ritz,et al.  Statin use and the risk of Parkinson disease , 2008, Neurology.

[111]  J. Bolam,et al.  Living on the edge with too many mouths to feed: Why dopamine neurons die , 2012, Movement disorders : official journal of the Movement Disorder Society.

[112]  D. Jennings,et al.  Can we image premotor Parkinson disease? , 2009, Neurology.

[113]  P. Löschmann,et al.  Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.

[114]  E. Arenas,et al.  Differential Effects of Glial Cell Line‐Derived Neurotrophic Factor and Neurturin on Developing and Adult Substantia Nigra Dopaminergic Neurons , 1999, Journal of neurochemistry.

[115]  S. Snyder,et al.  Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A , 1997, Nature Medicine.

[116]  B. Roux,et al.  Explaining why Gleevec is a specific and potent inhibitor of Abl kinase , 2013, Proceedings of the National Academy of Sciences.

[117]  E. Tolosa,et al.  The premotor phase of Parkinson's disease. , 2007, Parkinsonism & related disorders.

[118]  A. Smith,et al.  Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[119]  Y. Agid,et al.  Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. , 1997, Histology and histopathology.

[120]  Richard W. Murrow,et al.  Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[121]  P. James An Essay on the Shaking Palsy , 1817, The Medico-Chirurgical Journal and Review.

[122]  J. Schulz,et al.  Gene therapy in Parkinson’s disease , 2004, Cell and Tissue Research.

[123]  A. Korczyn Dopaminergic drugs in development for Parkinson's disease. , 2003, Advances in neurology.

[124]  J. Parkinson An Essay on the Shaking Palsy , 2002 .

[125]  C. Hawkes,et al.  Olfaction in neurodegenerative disorder. , 2006, Advances in oto-rhino-laryngology.

[126]  R. Ridley,et al.  Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease , 2005, The Journal of Neuroscience.

[127]  Philippe Hantraye,et al.  Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia , 2009, Science Translational Medicine.

[128]  B. de Strooper,et al.  Gene therapeutic strategies for neurodegenerative diseases. , 2000, Current opinion in molecular therapeutics.

[129]  A. Schapira,et al.  Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. , 2004, JAMA.

[130]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[131]  D. Weintraub,et al.  Parkinson's disease--Part 2: Treatment of motor symptoms. , 2008, The American journal of managed care.

[132]  K. Dujardin,et al.  A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. , 2008, Brain : a journal of neurology.

[133]  Jeffrey H. Kordower,et al.  The role of α-synuclein in Parkinson's disease: insights from animal models , 2003, Nature Reviews Neuroscience.

[134]  M. Yamada,et al.  Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. , 2005, Human gene therapy.

[135]  Jeffrey H Kordower,et al.  The role of alpha-synuclein in Parkinson's disease: insights from animal models. , 2003, Nature reviews. Neuroscience.

[136]  A. Antonini,et al.  Continuous dopaminergic stimulation achieved by duodenal levodopa infusion , 2008, Neurological Sciences.

[137]  A. Benabid Targeting the caudal intralaminar nuclei for functional neurosurgery of movement disorders , 2009, Brain Research Bulletin.

[138]  D. Grosset,et al.  The role of radiotracer imaging in Parkinson disease , 2005, Neurology.

[139]  R. Bartus,et al.  Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[140]  M. Hely,et al.  Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years , 2005, Movement disorders : official journal of the Movement Disorder Society.

[141]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.

[142]  M. Caldwell,et al.  Development of stem cell-based therapies for Parkinson's disease , 2016, The International journal of neuroscience.

[143]  E. Yoshikawa,et al.  Microglial activation and dopamine terminal loss in early Parkinson's disease , 2005, Annals of neurology.

[144]  Anatol C. Kreitzer,et al.  Striatal mechanisms underlying movement, reinforcement, and punishment. , 2012, Physiology.

[145]  C. Fall,et al.  Pramipexole Reduces Reactive Oxygen Species Production In Vivo and In Vitro and Inhibits the Mitochondrial Permeability Transition Produced by the Parkinsonian Neurotoxin Methylpyridinium Ion , 1998, Journal of neurochemistry.

[146]  A. Schapira,et al.  Pramipexole protects against MPTP toxicity in non‐human primates , 2006, Journal of neurochemistry.

[147]  H. Bergman,et al.  Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. , 1990, Science.

[148]  J. Villemure,et al.  Effect on mood of subthalamic DBS for Parkinson’s disease A consecutive series of 24 patients , 2002, Neurology.

[149]  I. Liste,et al.  Progress in Stem Cell Therapy for Major Human Neurological Disorders , 2013, Stem Cell Reviews and Reports.

[150]  W. Le,et al.  Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum , 2001, Brain Research.

[151]  O. Rascol “Disease-modification” trials in Parkinson disease: Target populations, endpoints and study design , 2009, Neurology.

[152]  M. Poulter,et al.  Neuroimmunophilins: A novel drug therapy for the reversal of neurodegenerative disease? , 2004, Neuroscience.

[153]  D. Mikulis,et al.  A new sensitive imaging biomarker for Parkinson disease? , 2009, Neurology.

[154]  C. Mariani,et al.  Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[155]  Y. Smith,et al.  Glutamate and GABA receptors and transporters in the basal ganglia: What does their subsynaptic localization reveal about their function? , 2006, Neuroscience.

[156]  W. Oertel,et al.  Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. , 2004, Brain : a journal of neurology.

[157]  T. Dawson,et al.  The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders , 2001, Trends in Neurosciences.

[158]  O. Lindvall,et al.  Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. , 2012, Cell reports.

[159]  L. Raymond,et al.  Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease , 2010, Trends in Neurosciences.

[160]  Suk-Ho Lee,et al.  Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. , 2011, The Journal of clinical investigation.

[161]  H. Reichmann,et al.  Olfactory function in Parkinsonian syndromes , 2002, Journal of Clinical Neuroscience.

[162]  H. Uylings,et al.  A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[163]  J. Lindon,et al.  'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[164]  Timothy Lynch,et al.  Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. , 2005, American journal of human genetics.

[165]  E. Tolosa Movement disorders: advances on many fronts , 2007, The Lancet Neurology.

[166]  Jeppe Falsig,et al.  Progressive Degeneration of Human Mesencephalic Neuron-Derived Cells Triggered by Dopamine-Dependent Oxidative Stress Is Dependent on the Mixed-Lineage Kinase Pathway , 2005, The Journal of Neuroscience.

[167]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[168]  Angelo Antonini,et al.  Parkinson's disease: the non-motor issues. , 2011, Parkinsonism & related disorders.

[169]  P. Carvey,et al.  Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole , 2005, Journal of Neural Transmission.

[170]  Y. Kitamura,et al.  Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. , 1998, Molecular pharmacology.

[171]  O. Lindvall,et al.  Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. , 2009, Trends in pharmacological sciences.

[172]  B. Hyman,et al.  Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. , 2004, The Journal of biological chemistry.

[173]  T. Dawson,et al.  Nitric oxide neurotoxicity , 1996, Journal of Chemical Neuroanatomy.

[174]  A. Benabid,et al.  Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[175]  P. Brundin,et al.  Critical issues of clinical human embryonic stem cell therapy for brain repair , 2008, Trends in Neurosciences.

[176]  K. Lim,et al.  Molecular Events Underlying Parkinson’s Disease – An Interwoven Tapestry , 2013, Front. Neurol..

[177]  C D Marsden,et al.  Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.

[178]  T. Iwatsubo,et al.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[179]  C. Olanow,et al.  Impairment of the ubiquitin‐proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures , 2002, Journal of neurochemistry.

[180]  L. Defebvre,et al.  Influence of chronic bilateral stimulation of the subthalamic nucleus on cognitive function in Parkinson's disease , 2001, Journal of Neurology.

[181]  Sheng Pan,et al.  Using ‘omics’ to define pathogenesis and biomarkers of Parkinson’s disease , 2010, Expert review of neurotherapeutics.

[182]  K P Bhatia,et al.  The role of DAT-SPECT in movement disorders , 2008, Journal of Neurology, Neurosurgery & Psychiatry.

[183]  J L Vitek,et al.  Mood changes with deep brain stimulation of STN and GPi: results of a pilot study , 2003, Journal of neurology, neurosurgery, and psychiatry.

[184]  Joel S Perlmutter,et al.  Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. , 2002, Archives of neurology.

[185]  N. Hattori,et al.  [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. , 2004, Rinsho shinkeigaku = Clinical neurology.

[186]  Voon Wee Yong,et al.  Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients , 1986, Neuroscience Letters.

[187]  J. Jankovic,et al.  A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. , 2002, Parkinsonism & related disorders.

[188]  Anthony E. Lang,et al.  Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.

[189]  Han-Joon Kim,et al.  Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease , 2015 .

[190]  V. Grill,et al.  Effects of Diazoxide on Gene Expression in Rat Pancreatic Islets Are Largely Linked to Elevated Glucose and Potentially Serve to Enhance β-Cell Sensitivity , 2007, Diabetes.

[191]  C. Moussa,et al.  Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. , 2013, Human molecular genetics.

[192]  北田 徹 Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1999 .

[193]  E. Zamrini,et al.  Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. , 1997, The American journal of pathology.

[194]  Eugene M. Johnson,et al.  MIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE , 2008, Neurology.

[195]  John E. Duda,et al.  Olfactory Dysfunction in Parkinson’s Disease , 2007, Neurosignals.

[196]  Belinda Wilson,et al.  Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[197]  D. Surmeier,et al.  Floor plate-derived dopamine neurons from hESCs efficiently engraft in animal models of PD , 2011, Nature.

[198]  V. Wheelock,et al.  Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[199]  Bonifati,et al.  Association between early-onset Parkinson's disease and mutations in the parkin gene. , 2000, The New England journal of medicine.

[200]  H. Gendelman,et al.  Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons , 2008, PloS one.

[201]  S. Paul,et al.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[202]  M. Mattson,et al.  Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease , 2002, Journal of neurochemistry.

[203]  R. Hauser,et al.  Transplanted dopaminergic neurons develop PD pathologic changes: A second case report , 2008, Movement disorders : official journal of the Movement Disorder Society.

[204]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[205]  R. de Caterina,et al.  Statins and stroke: evidence for cholesterol-independent effects , 2002 .

[206]  R. Barker Developing stem cell therapies for Parkinson's disease: waiting until the time is right. , 2014, Cell stem cell.

[207]  A. Johnson,et al.  Olfactory function in patients with Parkinson's disease. , 1975, Journal of chronic diseases.

[208]  R. Barker,et al.  Skin and platelet α-synuclein as peripheral biomarkers of Parkinson's disease , 2005, Neuroscience Letters.

[209]  Albert Hofman,et al.  Serum cholesterol levels and the risk of Parkinson's disease. , 2006, American journal of epidemiology.

[210]  A. Stiggelbout,et al.  Systematic evaluation of rating scales for impairment and disability in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[211]  Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease , 2007, Neurology.

[212]  A. Crossman Neural mechanisms in disorders of movement. , 1989, Comparative biochemistry and physiology. A, Comparative physiology.

[213]  D. Bozyczko‐Coyne,et al.  Inhibition of mixed lineage kinase 3 attenuates MPP+-induced neurotoxicity in SH-SY5Y cells , 2004, Brain Research.

[214]  Robert E. Burke,et al.  Axon degeneration in Parkinson's disease , 2013, Experimental Neurology.

[215]  B. Schmand,et al.  Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's Disease , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[216]  D. Standaert,et al.  Rationale for and use of NMDA receptor antagonists in Parkinson's disease. , 2004, Pharmacology & therapeutics.

[217]  A. Rezai,et al.  AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial , 2011, The Lancet Neurology.

[218]  A. Siderowf,et al.  A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. , 2004, Archives of neurology.

[219]  G. Siegel,et al.  Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain , 2001, Journal of Chemical Neuroanatomy.

[220]  M. Beal,et al.  Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice , 1998, Brain Research.

[221]  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.

[222]  David S. Park,et al.  Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[223]  C. Ustun,et al.  Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. , 2008, Clinical therapeutics.

[224]  M. Kohno,et al.  Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro , 1994, Brain Research.

[225]  H. Adami,et al.  Epidemiology and etiology of Parkinson’s disease: a review of the evidence , 2011, European Journal of Epidemiology.

[226]  David S. Park,et al.  Animal Models of Parkinson's Disease , 2011, Parkinson's disease.

[227]  P. Calabresi,et al.  Direct and indirect pathways of basal ganglia: a critical reappraisal , 2014, Nature Neuroscience.

[228]  C. Adler,et al.  Sniffing out Parkinson Disease: Can Olfactory Testing Differentiate Parkinsonian Disorders? , 2007, The neurologist.

[229]  R. Bakay,et al.  Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial , 2008, The Lancet Neurology.

[230]  W. Slikker,et al.  Neuroprotective Efficacy of a New Brain-Penetrating C-Abl Inhibitor in a Murine Parkinson’s Disease Model , 2013, PloS one.

[231]  J. Troncoso,et al.  Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function , 2010, Proceedings of the National Academy of Sciences.

[232]  V. Bolshakov,et al.  ES cell-derived renewable and functional midbrain dopaminergic progenitors , 2011, Proceedings of the National Academy of Sciences.

[233]  F. Mcdowell,et al.  Levodopa, Parkinson's disease, and hypotension. , 1970, Annals of internal medicine.

[234]  H. Gendelman,et al.  Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. , 2007, Journal of leukocyte biology.

[235]  P. Riederer,et al.  Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. , 1994, Neuroscience letters.

[236]  B. Shephard,et al.  Olfactory function in atypical parkinsonian syndromes , 1995, Acta neurologica Scandinavica.

[237]  E. Esposito,et al.  Non-steroidal anti-inflammatory drugs in Parkinson's disease , 2007, Experimental Neurology.

[238]  Eric Jacobs,et al.  Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease , 2005, Annals of neurology.

[239]  Thomas Hummel,et al.  Olfactory loss may be a first sign of idiopathic Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[240]  David Blum,et al.  Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease , 2001, Progress in Neurobiology.

[241]  M. Stern The preclinical detection of Parkinson's disease: Ready for prime time? , 2004, Annals of neurology.

[242]  P. Liberini,et al.  Olfaction in Parkinson’s disease: methods of assessment and clinical relevance , 2000, Journal of Neurology.

[243]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[244]  G. Linazasoro,et al.  Dopaminergic agonists in Parkinson's disease. , 2014, Neurologia.

[245]  H. Gendelman,et al.  Nitrated Alpha-Synuclein and Microglial Neuroregulatory Activities , 2008, Journal of Neuroimmune Pharmacology.

[246]  P. Riederer,et al.  Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. , 1994, Neuroscience letters.

[247]  M. Beal,et al.  Somatic mitochondrial DNA mutations in single neurons and glia , 2005, Neurobiology of Aging.

[248]  C A Ross,et al.  Synphilin‐1 is present in Lewy bodies in Parkinson's disease , 2000, Annals of neurology.

[249]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[250]  Jochen Klucken,et al.  Hsp70 Reduces α-Synuclein Aggregation and Toxicity* , 2004, Journal of Biological Chemistry.

[251]  T. Dawson,et al.  Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons , 2001, The European journal of neuroscience.

[252]  W. Poewe Parkinson disease: Treatment of the nonmotor symptoms of Parkinson disease , 2010, Nature Reviews Neurology.

[253]  Z. Zádori,et al.  Mesenchymal Stem Cells of Dental Origin-Their Potential for Anti-inflammatory and Regenerative Actions in Brain and Gut Damage , 2016, Current neuropharmacology.

[254]  D. Standaert,et al.  Targeted Overexpression of Human &agr;-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease , 2008, Journal of neuropathology and experimental neurology.

[255]  D. Bowers,et al.  Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: The COMPARE Trial , 2009, Annals of neurology.

[256]  O. Rascol,et al.  Neuroprotection in Parkinson's Disease , 1996, The Lancet.

[257]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[258]  R. Barker,et al.  Metabolomic analysis of urine and serum in Parkinson’s disease , 2008, Metabolomics.

[259]  A. Björklund,et al.  Neural grafting in Parkinson's disease unraveling the mechanisms underlying graft-induced dyskinesia. , 2010, Progress in brain research.

[260]  Y. Agid,et al.  Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[261]  Makoto Hashimoto,et al.  Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.

[262]  R. Constantinescu Update on the use of pramipexole in the treatment of Parkinson’s disease , 2008, Neuropsychiatric disease and treatment.

[263]  N. Ogawa,et al.  Immunosuppressive (FK506) and non-immunosuppressive (GPI1046) immunophilin ligands activate neurotrophic factors in the mouse brain , 2003, Brain Research.

[264]  Paresh K Doshi,et al.  Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[265]  T. Hummel,et al.  'Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. , 1997, Chemical senses.

[266]  J. Milbrandt,et al.  Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons , 1998, The Journal of Neuroscience.

[267]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[268]  G C Cotzias,et al.  Modification of Parkinsonism--chronic treatment with L-dopa. , 1969, The New England journal of medicine.

[269]  S. Harik Changes in the glucose transporter of brain capillaries. , 1992, Canadian journal of physiology and pharmacology.

[270]  I. Wilson,et al.  Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism , 2003, Nature Reviews Drug Discovery.

[271]  A. Siderowf,et al.  Premotor Parkinson's disease: Clinical features and detection strategies , 2009, Movement disorders : official journal of the Movement Disorder Society.

[272]  Anthony H V Schapira,et al.  Etiology and pathogenesis of Parkinson disease. , 2009, Neurologic clinics.

[273]  D. Standaert,et al.  Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity , 2008, Molecular Brain.

[274]  J. Jankovic,et al.  Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[275]  H. Shill,et al.  Abnormal serum concentrations of proteins in Parkinson's disease. , 2009, Biochemical and biophysical research communications.

[276]  H. You,et al.  Association of Olfactory Bulb Volume and Olfactory Sulcus Depth with Olfactory Function in Patients with Parkinson Disease , 2011, American Journal of Neuroradiology.

[277]  A. Carlsson,et al.  3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.

[278]  R. Duvoisin,et al.  Treatment of parkinsonism with levodopa. , 1969, Archives of neurology.

[279]  D. Goldstein,et al.  Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases. , 2009, Parkinsonism & related disorders.

[280]  N. Xiong,et al.  VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson’s disease , 2011, Gene Therapy.

[281]  Alexandra Durr,et al.  How much phenotypic variation can be attributed to parkin genotype? , 2003, Annals of neurology.

[282]  L. Honig Relationship between caffeine intake and Parkinson disease. , 2000, JAMA.

[283]  P. Mcgeer,et al.  The Role of Anti-Inflammatory Agents in Parkinson’s Disease , 2007, CNS drugs.

[284]  G. Baltuch,et al.  Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safety. , 2002, Journal of neurosurgery.

[285]  J. Langston,et al.  The parkinson's complex: Parkinsonism is just the tip of the iceberg , 2006, Annals of neurology.

[286]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan , 2007, Movement disorders : official journal of the Movement Disorder Society.

[287]  Dd Amsterdam Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: A comparison of neuropsychological effects , 2005 .

[288]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[289]  T. Hirokawa,et al.  Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. , 2003, Biochemical and biophysical research communications.

[290]  J. Duda,et al.  Olfaction as a biomarker in Parkinson's disease. , 2010, Biomarkers in medicine.

[291]  B. Hyman,et al.  Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.

[292]  M. Feany,et al.  Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. , 2005, Nature neuroscience.

[293]  I. Módy,et al.  NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release. , 1995, Trends in pharmacological sciences.

[294]  L. Schmued,et al.  Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model. , 2014, Neurotoxicology.

[295]  A. Lang,et al.  Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.

[296]  H M M Smeding,et al.  Pathological Gambling after bilateral STN stimulation in Parkinson disease , 2008 .

[297]  S Blond,et al.  Subthalamic nucleus stimulation induces deficits in decoding emotional facial expressions in Parkinson’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[298]  Mark Stacy,et al.  Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease , 2006, Annals of neurology.

[299]  R. Barker,et al.  Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. , 2005, Neuroscience letters.

[300]  Makoto Hashimoto,et al.  Transgenic Models of α‐Synuclein Pathology , 2003 .

[301]  T. Dawson,et al.  Parkin mediates the degradation‐independent ubiquitination of Hsp70 , 2008, Journal of neurochemistry.

[302]  C. Ross,et al.  Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[303]  C. Ross,et al.  α-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells , 2005, The Journal of Neuroscience.

[304]  P. Perozzo,et al.  Chronic Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson’s Disease: Effects on Cognition, Mood, Anxiety and Personality Traits , 2006, European Neurology.

[305]  D. Calne,et al.  Bromocriptine in Parkinsonism , 1974, British medical journal.

[306]  H. Mochizuki,et al.  The promises of stem cells: stem cell therapy for movement disorders. , 2014, Parkinsonism & related disorders.

[307]  G. Wooten,et al.  Maternal inheritance in Parkinson's disease , 1997, Annals of neurology.

[308]  Mark P Mattson,et al.  Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. , 2006, Antioxidants & redox signaling.

[309]  P. Hogarth,et al.  Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. , 2005, Archives of neurology.

[310]  A. Schapira Mitochondria in the aetiology and pathogenesis of Parkinson's disease , 2008, The Lancet Neurology.

[311]  Yoav Ben-Shlomo,et al.  The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen , 2013, BMC Neurology.

[312]  M. Stern,et al.  Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. , 2005, Journal of neurosurgery.

[313]  W. Matson,et al.  Metabolomic profiling to develop blood biomarkers for Parkinson's disease. , 2008, Brain : a journal of neurology.

[314]  M. Merello,et al.  Deep Brain Stimulation of the Subthalamic Nucleus for the Treatment of Parkinson's Disease , 2008 .

[315]  J. Brotchie,et al.  Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials , 2013, Movement disorders : official journal of the Movement Disorder Society.

[316]  J. Fantini,et al.  Therapeutic Strategies for Neurodegenerative Diseases , 2015 .

[317]  H. Reichmann,et al.  Biopsies of olfactory epithelium in patients with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.